Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 5/20 | 0.36 |
| ▸ | ATG7 | O95352 | 2/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232106 | 0.86 | LMNA (0.35) | LMNASMN1; SMN2TYMS | |
| SCHEMBL17232090 | 0.84 | TK1 (0.35) | TYMS | |
| SCHEMBL13169197 | 0.72 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL17732550 | 0.72 | LMNA (0.48) | LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15459905 | 0.72 | LMNA (0.48) | LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL19749043 | 0.72 | LMNA (0.32) | LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL16234376 | 0.70 | TK1 (0.48) | LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15788425 | 0.68 | LMNA (0.76) | LMNASMN1; SMN2ALOX12ADRA1ATYMS | |
| SCHEMBL25520885 | 0.68 | LMNA (0.76) | LMNASMN1; SMN2ALOX12ADRA1ATYMS | |
| SCHEMBL18744135 | 0.68 | LMNA (0.76) | LMNASMN1; SMN2ALOX12ADRA1ATYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | LMNA 4073/4885SMN1; SMN2 3222/4885ALOX12 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.